• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Medtronic’s Equity-Focused Nell-EQ Oximetry Advance Prompt Strategic Reassessment From MDT Investors?

    Simply Wall St·06/19/2026 11:27:12
    Listen to the news
    • Earlier in June 2026, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system with Nell-EQ intelligent processor, aiming to improve oxygen saturation and pulse rate monitoring accuracy across diverse skin tones and care settings while aligning with new ISO 80601-2-61:2026 standards.
    • This development, alongside recalls of a small number of Deep Brain Stimulation pocket adaptor kits with incorrect use-by dates and an expanded European distribution agreement for Retia Medical’s Argos Cardiac Output Monitor, highlights Medtronic’s simultaneous focus on innovation, product quality control, and broader participation in advanced monitoring markets.
    • We’ll now examine how FDA clearance for the Nell-EQ pulse oximetry system and its equity-focused design could influence Medtronic’s investment narrative.

    We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Medtronic Investment Narrative Recap

    To own Medtronic, you need to believe its diversified device portfolio and steady innovation can outweigh margin pressure, execution risk in new platforms, and ongoing restructuring around Diabetes. The Nellcor Nell-EQ clearance strengthens Medtronic’s monitoring story and fits its push into higher value technologies, but it does not materially shift the near term earnings catalyst or the key risk around mix driven margin pressure and large scale product ramp execution.

    Among recent announcements, the expanded Western European distribution of Retia Medical’s Argos Cardiac Output Monitor looks most connected to the Nell-EQ news. Together, they underline Medtronic’s deeper move into advanced monitoring, which could support the longer term catalyst of richer, data enabled ecosystems, even as analysts still flag nearer term concerns about margins, utilization trends, and the timing and impact of the Diabetes spin off.

    Yet while the innovation story is appealing, investors should also be aware that...

    Read the full narrative on Medtronic (it's free!)

    Medtronic's narrative projects $40.7 billion revenue and $6.4 billion earnings by 2029. This requires 4.6% yearly revenue growth and a $1.8 billion earnings increase from $4.6 billion today.

    Uncover how Medtronic's forecasts yield a $105.76 fair value, a 33% upside to its current price.

    Exploring Other Perspectives

    MDT 1-Year Stock Price Chart
    MDT 1-Year Stock Price Chart

    Some of the lowest analysts were already assuming only about 2 percent annual revenue growth and earnings of roughly US$6.2 billion by 2029, so if you are weighing this new monitoring news against those cautious expectations, it is worth asking whether the pessimism around margins and growth still holds up or needs a fresh look.

    Explore 8 other fair value estimates on Medtronic - why the stock might be worth as much as 33% more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.